Scout | Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer

This opportunity is no longer accepting applications.

grant

Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer

This grant opportunity supports the development of an innovative treatment approach using antibody-drug conjugates (ADCs) combined with radionuclides for cancer therapy. The project aims to overcome the limitations of ADCs, such as cancer resistance and ineffective drug delivery, by adding radionuclides that enable diagnostic imaging and enhance therapeutic effects. The use of diagnostic radio…

Source

Agency: National Institutes of Health

Program: SBIR

Dates

Opportunity Released: August 2, 2024

Open for Submission: August 2, 2024

Application Window Closes: October 18, 2024

Keywords

antibody-drug conjugates

radiopharmaceuticals

theranostics

cancer treatment

monoclonal antibodies

radionuclides

diagnostic imaging

targeted therapy

beta particles

alpha particles

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers